Nirmish R Shah

List of Publications by Year
in descending order

114 papers	1,543 citations	361413 20 h-index	414414 32 g-index
123 all docs	123 docs citations	123 times ranked	1647 citing authors

#	Article	IF	Citations
1	Severe Persistent Pain and Inflammatory Biomarkers in Sickle Cell Disease: An Exploratory Study. Biological Research for Nursing, 2022, 24, 24-30.	1.9	4
2	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	7.4	37
3	Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. American Journal of Hematology, 2022, 97, 603-612.	4.1	25
4	Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert Review of Hematology, 2022, 15, 167-173.	2.2	19
5	Perspectives of individuals with sickle cell disease on barriers to care. PLoS ONE, 2022, 17, e0265342.	2.5	13
6	Improving Pain Assessment Using Vital Signs and Pain Medication for Patients With Sickle Cell Disease: Retrospective Study. JMIR Formative Research, 2022, 6, e36998.	1.4	1
7	Effective Recruitment Strategies for a Sickle Cell Patient Registry Across Sites from the Sickle Cell Disease Implementation Consortium (SCDIC). Journal of Immigrant and Minority Health, 2021, 23, 725-732.	1.6	10
8	An Interrupted Time Series Analysis of the Dissemination of a Sickle Cell Vaso-Occlusive Episode Treatment Algorithm and a Case Management Referral Form for Individuals With Sickle Cell Disease in the Emergency Department. Journal of Emergency Nursing, 2021, 47, 40-49.e1.	1.0	3
9	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. Transplantation and Cellular Therapy, 2021, 27, 181.e1-181.e9.	1.2	18
10	â€œPain is Subjectiveâ€• A Mixed-Methods Study of Provider Attitudes and Practices Regarding Pain Management in Sickle Cell Disease Across Three Countries. Journal of Pain and Symptom Management, 2021, 61, 474-487.	1.2	13
11	Pain Intensity Assessment in Sickle Cell Disease Patients Using Vital Signs During Hospital Visits. Lecture Notes in Computer Science, 2021, 12662, 77-85.	1.3	1
12	Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Therapeutic Advances in Hematology, 2021, 12, 204062072110011.	2.5	13
13	Sickle cell disease is a global prototype for integrative research and healthcare. Genetics & Genomics Next, 2021, 2, e10037.	1.5	10
14	Symptom Monitoring in Children With Life-Threatening Illness. Advances in Nursing Science, 2021, 44, 268-278.	1.1	3
15	Can subjective pain be inferred from objective physiological data? Evidence from patients with sickle cell disease. PLoS Computational Biology, 2021, 17, e1008542.	3.2	4
16	The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US. Current Medical Research and Opinion, 2021, 37, 761-768.	1.9	3
17	Seriously ill pediatric patient, parent, and clinician perspectives on visualizing symptom data. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1518-1525.	4.4	5
18	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24

#	Article	IF	Citations
19	ELIPSIS: developing tools to better understand VOC in SCD. Blood, 2021, 137, 1987-1988.	1.4	2
20	Patient Perspectives of Sickle Cell Management in the Emergency Department. Critical Care Nursing Quarterly, 2021, 44, 160-174.	0.8	12
21	Dissemination of Evidence-Based Recommendations for Sickle Cell Disease to Primary Care and Emergency Department Providers in North Carolina: A Cost Benefit Analysis. Journal of Health Economics and Outcomes Research, 2021, 8, 18-28.	1.2	2
22	Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and Î²-thalassemia. Journal of the National Medical Association, 2021, 113, 170-176.	0.8	2
23	Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. JMIR Research Protocols, 2021, 10, e29014.	1.0	14
24	Severe Pain Profiles and Associated Sociodemographic and Clinical Characteristics in Individuals With Sickle Cell Disease. Clinical Journal of Pain, 2021, 37, 669-677.	1.9	3
25	A reanalysis of pain crises data from the pivotal l-glutamine in sickle cell disease trial. Contemporary Clinical Trials, 2021, 110, 106546.	1.8	9
26	A Needs Assessment of Persons With Sickle Cell Disease in a Major Medical Center in North Carolina. North Carolina Medical Journal, 2021, 82, 312-320.	0.2	0
27	Awareness and Use of the Sickle Cell Disease Toolbox by Primary Care Providers in North Carolina. Journal of Primary Care and Community Health, 2021, 12, 215013272110490.	2.1	1
28	Longâ€term biological effects in sickle cell disease: insights from a postâ€crizanlizumab study. British Journal of Haematology, 2021, 195, e150-e153.	2.5	4
29	Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS ONE, 2021, 16, e0258638.	2.5	13
30	Classification of Pain Dynamics in Sickle Cell Disease from Mobile App Reporting. Blood, 2021, 138, 983-983.	1.4	0
31	Symptom Correlates Using Network Analysis in Pediatric Patients Undergoing Blood and Marrow Transplant. Blood, 2021, 138, 4978-4978.	1.4	0
32	Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease. Blood, 2021, 138, 2052-2052.	1.4	1
33	Prevalence of High BMI Status in Adults with Sickle Cell Disease. Blood, 2021, 138, 2039-2039.	1.4	0
34	Implementation and Preliminary Effectiveness of mHealth Apps for Improving Sickle Cell Disease Care during COVID-19: A Mixed-Methods Evaluation. Blood, 2021, 138, 3038-3038.	1.4	0
35	Impact of Gaps in Care during Adult Care Transfer in Sickle Cell Disease. Blood, 2021, 138, 2992-2992.	1.4	0
36	Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study. Blood, 2021, 138, 3100-3100.	1.4	3

#	Article	IF	Citations
37	Feasibility of implementing mobile technology-delivered mental health treatment in routine adult sickle cell disease care. Translational Behavioral Medicine, 2020, 10, 58-67.	2.4	18
38	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology,the, 2020, 7, e18-e27.	4.6	173
39	Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use. Journal of the American Board of Family Medicine, 2020, 33, 91-105.	1.5	23
40	User-Centered App Design for Acutely Ill Children and Adolescents. Journal of Pediatric Oncology Nursing, 2020, 37, 359-367.	1.5	12
41	Mobile Health Technology for Pediatric Symptom Monitoring. Nursing Research, 2020, 69, 142-148.	1.7	12
42	Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open, 2020, 10, e034147.	1.9	7
43	Tackling adherence in sickle cell disease with mHealth. Lancet Haematology,the, 2020, 7, e713-e714.	4.6	5
44	Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance â€“ the perspective of private and public payers. Journal of Medical Economics, 2020, 23, 1345-1355.	2.1	13
45	Development of a Severity Classification System for Sickle Cell Disease . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633.	1.9	12
46	Measuring Pain in Sickle Cell Disease using Clinical Text. , 2020, 2020, 5838-5841.		8
47	Patientâ€reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. American Journal of Hematology, 2020, 95, 1066-1074.	4.1	24
48	Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet Journal of Rare Diseases, 2020, 15, 178.	2.7	21
49	Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study. Blood, 2020, 136, 17-19.	1.4	2
50	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. JMIR Research Protocols, 2020, 9, e16319.	1.0	19
51	Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease. Blood Transfusion, 2020, 18, 200-207.	0.4	4
52	Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study. Journal of Health Economics and Outcomes Research, 2020, 7, 52-60.	1.2	21
53	Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease. Blood, 2020, 136, 33-33.	1.4	1
54	Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US. Blood, 2020, 136, 25-25.	1.4	5

#	Article	IF	Citations
55	Sex Based Differences in Sickle Cell Disease. Blood, 2020, 136, 37-37.	1.4	0
56	Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 396-402.	1.3	16
57	Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients. Transfusion, 2019, 59, 3102-3112.	1.6	23
58	Sickle cell disease complications: Prevalence and resource utilization. PLoS ONE, 2019, 14, e0214355.	2.5	53
59	Where Did They Go? Tracking Young Adult Follow-up During the Transition From Pediatric to Adult-Oriented Care. Clinical Pediatrics, 2019, 58, 1277-1283.	0.8	9
60	Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. Transfusion, 2019, 59, 2622-2628.	1.6	2
61	Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providersâ€™ perspective. PLoS ONE, 2019, 14, e0216414.	2.5	27
62	Continuous Pain Assessment Using Ensemble Feature Selection from Wearable Sensor Data. , 2019, 2019, 569-576.		4
63	A Protocol to Assess Feasibility, Acceptability, and Usability of Mobile Technology for Symptom Management in Pediatric Transplant Patients. Nursing Research, 2019, 68, 317-323.	1.7	9
64	Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity. Pediatric Blood and Cancer, 2019, 66, e27463.	1.5	42
65	Emergency Department Encounters, Hospitalizations and ED Reliance Among Medicaid Eligible Patients with Sickle Cell Disease in North Carolina. Blood, 2019, 134, 2113-2113.	1.4	2
66	Use of Mobile Health Apps and Wearable Technology to Assess Changes and Predict Pain During Treatment of Acute Pain in Sickle Cell Disease: Feasibility Study. JMIR MHealth and UHealth, 2019, 7, e13671.	3.7	36
67	Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study. Journal of Health Economics and Outcomes Research, 2019, 6, 106-117.	1.2	18
68	Hydroxyurea Prescription Fills and Adherence, Among Pediatric and Adult Medicaid Eligible Patients with Sickle Cell Disease in North Carolina. Blood, 2019, 134, 3391-3391.	1.4	0
69	Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States. Blood, 2019, 134, 4700-4700.	1.4	0
70	Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel. Blood, 2019, 134, 415-415.	1.4	3
71	How Does Sickle Cell Disease Severity Affect Patient Collection of Disability Insurance and Income: An Analysis of US Survey Data. Blood, 2019, 134, 5781-5781.	1.4	0
72	Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective. Blood, 2019, 134, 3464-3464.	1.4	1

#	Article	IF	Citations
73	Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 883-884.	2.0	9
74	Improving pain management in patients with sickle cell disease from physiological measures using machine learning techniques. Smart Health, 2018, 7-8, 48-59.	3.2	22
75	Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life. Pediatric Blood and Cancer, 2018, 65, e27081.	1.5	36
76	Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine, 2018, 36, 2356-2363.	3.8	11
77	Understanding patterns and correlates of daily pain using the Sickle cell disease Mobile Application to Record Symptoms via Technology (<scp>SMART</scp>). British Journal of Haematology, 2018, 183, 306-308.	2.5	3
78	Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism. Transfusion, 2018, 58, 2797-2806.	1.6	27
79	The sickle cell disease implementation consortium: Translating evidenceâ€based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395.	4.1	52
80	Customization of the TRU-PBMT App (Technology Recordings to better Understand Pediatric Blood and) Tj ETQq0 0 0 rgBT /Overlock 10	1.5	9
81	A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study. Blood, 2018, 132, 4910-4910.	1.4	1
82	Integrating Mobile Health Technology for Symptom Management in Acute Pediatric Blood and Marrow Transplant Patients. Blood, 2018, 132, 4726-4726.	1.4	1
83	Abstract Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional Feasibility Study. Journal of Medical Internet Research, 2018, 20, e10056.	4.3	16
84	Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review. Journal of Medical Internet Research, 2018, 20, e10940.	4.3	119
85	Trajectories of Sickle Cell Disease Severity during Transition to Adult Care. Blood, 2018, 132, 318-318.	1.4	0
86	Outpatient Healthcare Utilization and Rates of Co-Management Among Medicaid Patients with Sickle Cell Disease in North Carolina. Blood, 2018, 132, 4725-4725.	1.4	0
87	Hybrid Statistical and Mechanistic Mathematical Model Guides Mobile Health Intervention for Chronic Pain. Journal of Computational Biology, 2017, 24, 675-688.	1.6	3
88	Utilizing a Novel Mobile Health â€œSelfieâ€•Application to Improve Compliance to Iron Chelation in Pediatric Patients Receiving Chronic Transfusions. Journal of Pediatric Hematology/Oncology, 2017, 39, 223-229.	0.6	26
89	Attitudes of Primary Care Physicians Toward Sickle Cell Disease Care, Guidelines, and Comanaging Hydroxyurea With a Specialist. Journal of Primary Care and Community Health, 2017, 8, 37-40.	2.1	16
90	Advances in iron chelation therapy: transitioning to a new oral formulation. Drugs in Context, 2017, 6, 1-10.	2.2	20

#	Article	IF	Citations
91	Challenges in Shifting Management Responsibility From Parents to Adolescents With Sickle Cell Disease. Journal of Pediatric Nursing, 2016, 31, 678-690.	1.5	18
92	Trends in Sickle Cell Disease-related Priapism in U.S. Children's Hospitals. Urology, 2016, 89, 118-122.	1.0	10
93	Use of Mobile Technology to Monitor Pain and Reduce Outpatient, Emergency Department (ED), and Hospital Visits for Sickle Cell Pain Crisis. Blood, 2016, 128, 2390-2390.	1.4	0
94	Sickle cell disease is associated with iron mediated hypercoagulability. Journal of Thrombosis and Thrombolysis, 2015, 40, 182-185.	2.1	14
95	Usability and Feasibility of an mHealth Intervention for Monitoring and Managing Pain Symptoms in Sickle Cell Disease: The Sickle Cell Disease Mobile Application to Record SymptomsviaTechnology (SMART). Hemoglobin, 2015, 39, 162-168.	0.8	62
96	Differences in Pain Management Between Hematologists and Hospitalists Caring for Patients With Sickle Cell Disease Hospitalized for Vasoocclusive Crisis. Clinical Journal of Pain, 2014, 30, 266-268.	1.9	4
97	Patients Welcome the Sickle Cell Disease Mobile Application to Record SymptomsviaTechnology (SMART). Hemoglobin, 2014, 38, 99-103.	0.8	68
98	The Use of Mobile Technology for Intensive Training in Medication Management in the Pediatric Population. Blood, 2014, 124, 4842-4842.	1.4	2
99	Growing Pains â€“ Determination of Transfer and Transition from Pediatrics to Adult Outpatient Clinics for Patients with Sickle Cell Disease (SCD). Blood, 2014, 124, 3518-3518.	1.4	0
100	Effects of Sulforaphane Obtained from Broccoli Sprout Homogenate in Patients with Sickle Cell Disease (SCD). Blood, 2014, 124, 4931-4931.	1.4	0
101	The Use of Chronic Transfusions in Sickle Cell Disease for Non-Stroke Related Indications. Blood, 2014, 124, 4934-4934.	1.4	1
102	Characteristics of abdominal vein thrombosis in children and adults. Thrombosis and Haemostasis, 2013, 109, 625-632.	3.4	6
103	Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso-Occlusive Pain Crisis In Patients With Sickle Cell Disease. Blood, 2013, 122, 2241-2241.	1.4	8
104	Characterization of the hypercoagulable state in patients with sickle cell disease. Thrombosis Research, 2012, 130, e241-e245.	1.7	36
105	Severe fetal and neonatal hemolytic anemia due to a 198â€‰kb deletion removing the complete Î²â€globin gene cluster. Pediatric Blood and Cancer, 2012, 59, 941-944.	1.5	11
106	Complications of implantable venous access devices in patients with sickle cell disease. American Journal of Hematology, 2012, 87, 224-226.	4.1	24
107	Hypercoagulability in Pediatric Patients with Sickle Cell Disease and Correlation to Transcranial Doppler and Disease Severity. Blood, 2012, 120, 3221-3221.	1.4	0
108	Timing of the Initiation of Hydroxyurea and Hematologic Outcomes in Patients with Sickle Cell Disease (SCD). Blood, 2012, 120, 1004-1004.	1.4	0

#	Article	IF	Citations
109	Presentation and Outcomes for Children With Bone Marrow Necrosis and Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2011, 33, e316-e319.	0.6	8
110	Differences Between Hematologist and Hospitalist Caring for Patients with Sickle Cell Disease Hospitalized for Vaso-Occlusive Crisis,. Blood, 2011, 118, 4185-4185.	1.4	0
111	Complications of Implantable Venous Access Devices In Patients with Sickle Cell Disease. Blood, 2010, 116, 1649-1649.	1.4	0
112	Severe Fetal and Neonatal Anemia Due to Heterozygosity for a 198 Kb Deletion Removing the Entire Î²-Globin Gene Cluster. Blood, 2010, 116, 5171-5171.	1.4	0
113	Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients. Blood, 2010, 116, 4219-4219.	1.4	0
114	Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA).. Blood, 2009, 114, 2557-2557.	1.4	0